Genmab's CEO shares his perspective on how the company's work to develop innovative antibody therapeutics could change the lives of cancer patients in the future. Click here to watch the video.
Genmab is inviting researchers in academia and industry to experience the full power of the DuoBody® platform for bispecific antibody research and drug development. Explore the possibilities via our recently published Perspective in the journal mAbs and the renewed Open Innovation section on DuoBody.com.
Access our latest presentations and posters including daratumumab data presented at ASCO and our investor presentation at the Jefferies 2014 Global Healthcare Conference in our Download Library.